Results 231 to 240 of about 45,846 (267)

Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis. [PDF]

Ther Adv Med Oncol
Wang J, Ding B, Jing Z, Zhu Y, Gao L, Yao H, Tao T, Li X.   +7 more
europepmc   +1 more source

Economic value of extended-window intravenous alteplase in posterior circulation stroke: a Markov analysis based on the EXPECTS trial. [PDF]

Front Pharmacol
Ma Y, Lou Y, Chen M, Zeng Y.
europepmc   +1 more source

The price of safety and convenience: Urban shoppers' willingness to pay for hygienic market stalls and minimal processing of leafy vegetables in Kenya. [PDF]

PLoS One
Mwambi M, Opiyo P, Wafula A, Schreinemachers P, Roothaert R, de Bruyn J.   +5 more
europepmc   +1 more source

Assessment of cost-effectiveness threshold using a double-bounded dichotomous choice model. [PDF]

Public Health Pract (Oxf)
Kitano T, Tsuzuki S.
europepmc   +1 more source

Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China. [PDF]

Front Public Health
Fang R, Liang J, Wang T, Sheng F, Xu J.
europepmc   +1 more source

Peers are as persuasive as experts in reducing willingness to pay for sugary foods. [PDF]

Front Nutr
Arzumanyan N, Shestakova AN, Moiseeva V, Blank IB, Klucharev V, Davidovich A, Ntoumanis I.   +6 more
europepmc   +1 more source

An exploration of mediating mechanisms influencing willingness to pay for corporate social responsibility. [PDF]

Sci Rep
Ahmad S, Zhang Q, Ahmad Z, Ullah A.
europepmc   +1 more source

Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China. [PDF]

PLoS One
Kang S, Yang S, Jia Y, Zhao S.
europepmc   +1 more source